{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:15:54Z","timestamp":1790748954577,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T00:00:00Z","timestamp":1422835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T00:00:00Z","timestamp":1422835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/leu.2015.16","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T08:21:00Z","timestamp":1422865260000},"page":"1605-1608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Aberrant expression of CD123 (interleukin-3 receptor-\u03b1) on neoplastic mast cells"],"prefix":"10.1038","volume":"29","author":[{"given":"A","family":"Pardanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T K","family":"Kimlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Zblewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K K","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Rowinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,2]]},"reference":[{"key":"BFleu201516_CR1","doi-asserted-by":"publisher","first-page":"25999","DOI":"10.1074\/jbc.271.42.25999","volume":"271","author":"JM Woodcock","year":"1996","unstructured":"Woodcock JM, Bagley CJ, Zacharakis B, Lopez AF . A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all three ligands. J Biol Chem 1996; 271: 25999\u201326006.","journal-title":"J Biol Chem"},{"key":"BFleu201516_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.V68.1.46.46","volume":"68","author":"D Metcalf","year":"1986","unstructured":"Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ . Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 1986; 68: 46\u201357.","journal-title":"Blood"},{"key":"BFleu201516_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel A . CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2014; 2: 4.","journal-title":"Biomark Res"},{"key":"BFleu201516_CR4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777\u20131784.","journal-title":"Leukemia"},{"key":"BFleu201516_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10428190500272507","volume":"47","author":"S Florian","year":"2006","unstructured":"Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR et al. Detection of molecular targets on the surface of CD34+\/CD38\u2014 stem cells in various myeloid malignancies. Leuk Lymphoma 2006; 47: 207\u2013222.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201516_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/bjh.12978","volume":"166","author":"O Frolova","year":"2014","unstructured":"Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK et al. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol 2014; 166: 862\u2013874.","journal-title":"Br J Haematol"},{"issue":"5","key":"BFleu201516_CR7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","volume":"56","author":"Simon Z. He","year":"2014","unstructured":"He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID et al. A phase 1 study of the safety, pharmacokinetics, and anti-leukemic activity of the anti-CD123 monoclonal antibody, CSL360, in relapsed, refractory or high-risk acute myeloid leukemia (AML). Leuk Lymphoma 2014; e-pub ahead of print 20 November 2014; doi:10.3109\/10428194.2014.956316.","journal-title":"Leukemia & Lymphoma"},{"key":"BFleu201516_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2013.31.15_suppl.7029","volume":"31","author":"AE Frankel","year":"2013","unstructured":"Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. J Clin Oncol 2013; 31: 15.","journal-title":"J Clin Oncol"},{"key":"BFleu201516_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","volume":"124","author":"AE Frankel","year":"2014","unstructured":"Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014; 124: 385\u2013392.","journal-title":"Blood"},{"key":"BFleu201516_CR10","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.4049\/jimmunol.145.10.3432","volume":"145","author":"P Valent","year":"1990","unstructured":"Valent P, Besemer J, Sillaber C, Butterfield JH, Eher R, Majdic O et al. Failure to detect IL-3-binding sites on human mast cells. J Immunol 1990; 145: 3432\u20133437.","journal-title":"J Immunol"},{"key":"BFleu201516_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","volume":"125","author":"C Teodosio","year":"2010","unstructured":"Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Sanchez-Munoz L, Alvarez-Twose I, Nunez R et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010; 125: 719\u2013726.","journal-title":"J Allergy Clin Immunol"},{"key":"BFleu201516_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V120.21.1746.1746","volume":"120","author":"MT Moonim","year":"2012","unstructured":"Moonim MT, Kossier T, van Der Walt J, Wilkins B, Harrison CN, Radia DH . CD30\/CD123 expression in systemic mastocytosis does not correlate with aggressive disease. Blood 2012; 120: 21.","journal-title":"Blood"},{"key":"BFleu201516_CR13","first-page":"54","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"HP Horny","year":"2008","unstructured":"Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (eds) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th edn International Agency for Research and Cancer (IARC): Lyon, 2008; pp 54\u201363."},{"key":"BFleu201516_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ajh.23459","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A . Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013; 88: 612\u2013624.","journal-title":"Am J Hematol"},{"key":"BFleu201516_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2013-05-500959","volume":"122","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al. Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the Global D2201 trial. Blood 2013; 122: 21.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201516","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T14:02:13Z","timestamp":1690984933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,2]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFleu201516"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.16","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,2]]},"assertion":[{"value":"2 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AP received research funding from Stemline Therapeutics Inc. for the flow cytometry experiments. AP is Principal Investigator for a forthcoming clinical trial of SL-401 for treatment of myeloproliferative neoplasms. SL-401 is a CD123-targeting investigational drug manufactured by Stemline Therapeutics Inc. CB and ER are employees of Stemline Therapeutics Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}